 | NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insider Sells $616,250.00 in Stock
americanbankingnews.com - April 13 at 7:50 PM |
 | Cancer Anorexia Market Anticipated to Witness a Modest Growth at a CAGR of 10.92% During the Study Period 2018-2030 in the 7MM, Estimates DelveInsight
finanznachrichten.de - April 12 at 10:42 PM |
 | Global Cancer Anorexia Market Outlook to 2030: Epidemiology, Drugs, Unmet Needs, Pipeline & Development Activities, Competition
finance.yahoo.com - April 12 at 10:42 PM |
| NGM Biopharmaceuticals (NASDAQ:NGM) Shares Gap Down to $25.43
americanbankingnews.com - April 12 at 12:36 PM |
| NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Expected to Post Earnings of -$0.48 Per Share
americanbankingnews.com - April 1 at 8:16 PM |
| NGM Biopharmaceuticals (NASDAQ:NGM) Shares Down 6.8%
americanbankingnews.com - March 26 at 1:50 PM |
| Strength Seen in NGM Biopharmaceuticals (NGM): Can Its 6.7% Jump Turn into More Strength?
finance.yahoo.com - March 26 at 1:17 PM |
| Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
finance.yahoo.com - March 15 at 1:48 PM |
 | Gemini Therapeutics: Precision Medicine Company Focused On Dry AMD
seekingalpha.com - March 5 at 12:59 AM |
| NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 4 at 10:48 PM |
|
| NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 5:45 PM |
| NGM Bio to Present at the Cowen 41st Annual Health Care Conference
finance.yahoo.com - February 25 at 8:11 AM |
 | How this cancer-fighting company from China quietly landed as the Bay Area's latest biotech IPO
bizjournals.com - February 9 at 10:26 PM |
 | Geographic Atrophy Pipeline Report 2021: Therapeutic Evaluation, Drug Profiles, Unmet Needs, Prominent Companies
benzinga.com - February 9 at 10:26 PM |
| NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
finance.yahoo.com - February 9 at 8:28 AM |
| Could The NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - January 14 at 4:23 PM |
| NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
finance.yahoo.com - January 13 at 5:38 AM |
 | NGM Biopharmaceuticals Inc Registered Shs Strong Buy
markets.businessinsider.com - January 10 at 12:53 AM |
| NGM Bio prices $125M share offering
seekingalpha.com - January 7 at 5:48 PM |
| NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
finance.yahoo.com - January 5 at 10:54 PM |
| NGM Bio Announces Proposed Offering of Common Stock
finance.yahoo.com - January 4 at 8:20 PM |
| NGM Jan 2021 20.000 call
au.finance.yahoo.com - December 24 at 10:54 PM |
| NGM Jan 2021 15.000 call
au.finance.yahoo.com - December 24 at 12:51 AM |
| Is NGM A Good Stock To Buy Now?
finance.yahoo.com - December 12 at 5:17 AM |
| NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
finance.yahoo.com - December 9 at 6:10 PM |
| NGM Nov 2020 20.000 call
au.finance.yahoo.com - November 20 at 6:59 PM |
| NGM to Host Virtual R&D Day on December 9, 2020
feeds.benzinga.com - November 16 at 12:44 PM |
| Analyst Estimates: Here's What Brokers Think Of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) After Its Third-Quarter Report
finance.yahoo.com - November 15 at 1:11 PM |
| NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
finance.yahoo.com - November 13 at 9:39 AM |
| NGM Biopharmaceuticals EPS misses by $0.04, beats on revenue
seekingalpha.com - November 12 at 6:58 PM |
|
| NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 12 at 6:58 PM |
| NGM Bio to Present at Three Upcoming Investor Conferences
finance.yahoo.com - November 11 at 9:38 AM |
| If You Had Bought NGM Biopharmaceuticals (NASDAQ:NGM) Shares A Year Ago You'd Have Earned 46% Returns
finance.yahoo.com - November 9 at 12:36 PM |
| NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
finance.yahoo.com - November 5 at 9:25 AM |
| NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH
finance.yahoo.com - November 4 at 8:32 AM |
| Earnings Preview: NGM Biopharmaceuticals (NGM) Q3 Earnings Expected to Decline
finance.yahoo.com - November 3 at 2:21 PM |
 | I've owned, improved, and sold hundreds of businesses successfully. Here are the 6 areas you should be focusing on if you want to sell your business at its maximum value.
msn.com - October 27 at 12:47 PM |
| NGM expands oncology portfolio with first immuno-oncology development candidate
seekingalpha.com - October 19 at 1:46 PM |
| NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
markets.businessinsider.com - October 19 at 8:46 AM |
| Global Primary Sclerosing Cholangitis Market 2017-2020 & 2030 Featuring Gilead Sciences, HighTide Biopharma, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr Falk Pharma
markets.businessinsider.com - October 14 at 4:25 AM |
| Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.
feeds.benzinga.com - September 25 at 7:30 AM |
| NGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow
seekingalpha.com - August 31 at 3:33 PM |
| NGM Bio's aldafermin shows positive effect in NASH patients with advanced disease
seekingalpha.com - August 31 at 10:44 AM |
| NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
finance.yahoo.com - August 29 at 7:28 AM |
| NGM Bio a stock to watch ahead of key NASH presentation
seekingalpha.com - August 18 at 1:40 PM |
| NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020
finance.yahoo.com - August 18 at 8:39 AM |
| NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 12 at 10:34 PM |
| NGM Biopharmaceuticals EPS misses by $0.04, misses on revenue
seekingalpha.com - August 12 at 5:34 PM |
| NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
finance.yahoo.com - August 12 at 5:34 PM |
| We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
finance.yahoo.com - August 11 at 4:06 PM |
